What it is
GLOW is a fixed 70 mg community blend containing GHK-Cu, BPC-157, and TB-500. The formula combines copper-peptide signaling with two experimental repair pathways, but the blend itself does not have a validated human protocol.
Evidence boundary
Community fixed-ratio blend with no human trial validating the combination or its cycle.
Preparation and measurement
Reconstitution: 70 mg vial + 3 mL BAC = 23.33 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–4 | 2.33 mg total blend | 10 U (0.10 mL) | Once daily | 16.31 mg/week |
Weeks 1–4
- Dose
- 2.33 mg total blend
- Draw / measure
- 10 U (0.10 mL)
- Frequency
- Once daily
- Weekly total
- 16.31 mg/week
Weekly totals apply only during the active phase.
Titration rules
- The collected schedule uses a fixed 10 U daily draw; no automatic escalation is defined.
- Changing the draw changes all three components together. Separate vials are required when one component needs adjustment.
Cycle length and breaks
Use a defined 4-week daily block, then stop for 2–4 weeks and reassess.
What to monitor
- Skin and wound changes documented with consistent photos
- Pain, swelling, mobility, and injection-site reactions
- Avoid duplicate standalone GHK-Cu exposure unless the total copper-peptide amount is explicitly calculated
Practical rules
- Keep wound or injury measurements objective and consistent.
- Protect healing skin from excess sun exposure.
- Record the total weekly GHK-Cu exposure when any separate copper-peptide product is used.
Related protocols
KLOW Blend (80 mg) Peptide Protocol & DosingTri-Heal Blend (45 mg) Peptide Protocol & DosingGHK-Cu Peptide Protocol & DosingBPC-157 + TB-500 Peptide Stack & Dosing Supply & lot verification
Availability and batch-linked COA records for GLOW Blend (70 mg) Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes